Comprised of experts in infection and immune-related diseases

An Innovative New Drug Development Company

Developing therapeutics for bacterial sepsis, superbacteria infection and Alzheimer’s Disease

A global biopharmaceutical company

CONTRIBUTING TO GLOBAL HEALTH

HLB SCIENCE

HLB
SCIENCE’S

INNOVATIVE CORE TECHONOLGY IN LIFE SCIENCE AND MEDICINE

  • SEPSIS THERAPEUTICS
  • ANTIBIOTICS TARGETING SUPERBACTERIA
  • TREATMENT FOR ALZHEIMER’S DISEASE
  • DIAGNOSTIC KIT FOR ALZHEIMER’S DISEASE
  • LPS REMOVAL KIT

DD-S052P, and its three core concepts in targeting Sepsis and Superbacteria infection

DD-S052P is a novel antibiotic, capable of removing both bacteria and endotoxin.

Antibiotics that target sepsis primarily target the causative pathogens, but not the endotoxins released during pathogen apoptosis. Endotoxins may cause cytokine storms, which can exacerbate morbidity and cause patient death.

SEPSIS THERAPEUTICS

DD-A279 & DD-A514, TREATMENT AND DIAGNOSIS KIT FOR ALZHEIMER'S DISEASE

DD-A279 is a novel treatment for Alzheimer's Disease via modulation of LPS and gram-negative bacteria in the CNS. DD-A514 is a quick, accurate diagnosis kit for preemptive detection for the onset of Alzheimer's Disease.

Alzheimer's Disease has no know cure at this present time.
However,research indicates that LPS and gram-negative bacteria play a key role in the onset and progression of Alzheimer's Disease.

TREATMENT FOR ALZHEIMER`S DISEASES
pin
HLB SCIENCE INC.
6F, 66, Achasan-ro, Seongdong-gu, Seoul, Republic of Korea
  • Fax070-8280-0378
  • E-mailhlbscience@hlbscience.com
pin
HLB SCIENCE LABORATORY
806, Dongtan M Tower 8th floor, Dongtancheomdansaneop 1-ro, Hwaseong-si, Gyeonggi-do
  • Fax070-5165-0011
  • E-mailhlbscience@hlbscience.com